Evaluation of the Possible Effect of Inspiratory Muscle Training on Inflammation Markers and Oxidative Stress in Childhood Asthma

February 15, 2024 updated by: Ozden Gokcek, Ege University

As inflammation and oxidative stress increase in asthma patients, the severity of symptoms and clinical findings increase. Therefore, this study was planned to evaluate the possible effect of inspiratory muscle training (IMT) on inflammation markers and oxidative stress in childhood asthma.

The study included asthma patient; 35 routine medication, 35 drug therapy and inspiratory muscle training (IMT), and 35 healthy total 105 children aged 8-17 years. Demographic information and hemogram values were recorded. Functional capacity was evaluated with the 6-minute walking test, quality of life PedsQL, respiratory muscle strength oral pressure measuring device, respiratory function test, dyspnea severity with Modified Borg Scale. C-Reactive Protein (CRP), Periostin, Transforming Growth Factor-βeta (TGF-β), Total Antioxidant Status (TAS), Total Oxidant Status (TOS), Oxidative Stress Index (OSI) were analyzed. IMT was given with a Threshold IMT device for 7 days/6 weeks at 30% of maximal inspiratory pressure, and then a second evaluation was made.

Study Overview

Study Type

Interventional

Enrollment (Actual)

105

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Karsıyaka
      • İzmir, Karsıyaka, Turkey
        • Ege University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

8 years to 17 years (Child)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Have been diagnosed with asthma,
  • Between the ages of 8-17,
  • No asthma attack,
  • Cooperating with the study,
  • Without cerebral palsy, mental retardation or any other major neurological diagnosis,
  • Agreeing to participate in the study,
  • Cases whose medication has not been changed for at least three weeks.

Exclusion Criteria:

  • Presence of kyphoscoliosis that may affect respiration,
  • Having advanced postural alignment problem,
  • Having mental problems,
  • Having neuromuscular disease,
  • Making changes in the medications used in the last three weeks,
  • Presence of inflammatory diseases such as juvenile idiopathic arthritis.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Used routine medicine group
Followed 6 weeks
After the first evaluation was made, a second evaluation was made after 6 weeks of follow-up.
Active Comparator: Control Group
Health children
A healthy child compatible with the age and sex of the patient group was evaluated once.
Experimental: Inspiratory muscle training group
Threshold IMT was given this group. Applied for 7 days 6 weeks.
After the first evaluation was made, a second evaluation was made after 6 weeks of follow-up.

The MIP/MEP value of the group that will receive inspiratory muscle training was determined and Threshold IMT training was given with 30%.

In the training, the subjects were asked to sit in a relaxed position with their upper chest and shoulders relaxed.

After the nose clip was attached, the children were asked to inhale and exhale by tightly closing the mouthpiece of the instrument with their lips.

A 30-minute training session was carried out for 6 weeks, with 10-15 repetitive breathing apparatus and 5-10 seconds rest breaks every day.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Inflammatory marker
Time Frame: 6 weeks
We assessed C reaktive protein from Blood sample
6 weeks
Inflammatory marker
Time Frame: 6 weeks
We assessed TGF-B from Blood sample
6 weeks
Inflammatory marker
Time Frame: 6 weeks
We assessed Periostin from Blood sample
6 weeks
Oxidative stress
Time Frame: 6 weeks
We assessed Total oxidative level.
6 weeks
Oxidative stress
Time Frame: 6 weeks
We assessed total antioxidative level
6 weeks
Oxidative stress
Time Frame: 6 weeks
We assessed oxidative status index
6 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pulmonary function test
Time Frame: 6 weeks
Pulmonary function test was measured with a portable MiniSpirobank device
6 weeks
Respiratory muscle strength
Time Frame: 6 weeks
Respiratory muscle strength was measured using a portable (micro RPM brand) electronic mouth pressure measuring device according to ATS/ERS criteria
6 weeks
functional capacity
Time Frame: 6 weeks
functional capacity was assessed 6 MWT
6 weeks
Quality life
Time Frame: 6 weeks
Quality life was assessed PedsQl
6 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2019

Primary Completion (Actual)

June 30, 2020

Study Completion (Actual)

June 30, 2020

Study Registration Dates

First Submitted

March 3, 2022

First Submitted That Met QC Criteria

March 16, 2022

First Posted (Actual)

March 25, 2022

Study Record Updates

Last Update Posted (Actual)

February 20, 2024

Last Update Submitted That Met QC Criteria

February 15, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Asthma in Children

Clinical Trials on Used routine medicine

Subscribe